
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

MAY 10, 2017

WilmerHale client Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced the pricing of a registered underwritten public offering of 3,902,439 shares of its common stock at a price to the public of \$10.25 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be \$40 million.

The WilmerHale deal team representing Karyopharm includes [Steven Singer](#), [Jason Kropp](#), Craig Hilts and [Alex Civetta](#).

Read Karyopharm Therapeutics' [press release](#) for more information.